I'll do this in English, I hope that's okay, just to make sure everyone is on the same page here. Yes, my name is Jørgen Mann, I'm Danish, so that's the language side of it. Yeah, but I'd like you to tell you a story about the journey that Observe Medical is coming into, being an extremely commercial journey we are entering into. I mean, Observe Medical is a Nordic company, but with a global reach. Our ambitions go far beyond the Nordics. What you see here is actually the four pillars of how our commercial journey would be built on. So what we're looking at is the urine measurement part, which is a combination of products we have acquired from ConvaTec, and also our own Sippi product that was acquired some years back. We also have the Biim product, the pocketable ultrasound device, that we are working with prominently for Seniors to launch, and we also have an element of, let's say, an opportunistic approach to our mergers and acquisitions. If there are opportunities out there, we would definitely go for them. That That fits the way we are doing our business. The last icon you see there is a new one compared to what you've seen earlier. We are in a situation now where we have a distribution network that covers most of the world, primarily 80%, let's say, Europe, but we also have distribution partners in Asia and other areas. 25 countries are we at right now. We would like to try and explore that platform to take in innovative products that other companies have brought, are looking to bring to market, where we can use our distribution platform. This is a little bit the highlights of 2023. We have seen a build-up on the commercial journey. We have seen, the start of the year we started supplying the market with the Abdo-Pressure products, which is part of the ConvaTec portfolio. Very interesting product, very unique product, and it has also helped quite a bit in getting access to a distribution network that we are now working with. We also managed to get the CE certification, under our own legal manufacturing umbrella on the ConvaTec product, the UnoMeter 500. That was a huge achievement. It was not only the CE market. It also included establishing a partnership with a Chinese, in this case, manufacturer, a critical supplier, which was part of that process, which has brought us to a position now where we are able to supply a very competitive product into the market. The ConvaTec transition also was completed at the second half of the year. As you will know, we made an exclusive agreement to acquire it. Now that deal has now been completed in the sense that now a transaction has happened, that now we have access to these products and these brands also from a commercial perspective. The first shipments of UnoMeter 500 was happening in the late of the year, I mean September/October. We started shipping our products. Big step for us, because that was to be the direct revenue generator for us. Biim, we took another step on the Biim journey, having Fresenius buying another 20 pieces. It's not a huge amount; we'll come back to some of the details of the Fresenius situation, but it is seen from our side a commitment, and also there was a prolongation of a contract on that part. So we did see a et's say a commitment from Fresenius to continue the journey in, let's say, validating the relevance of Biim, both from a clinical but also from a business perspective, seen from business Fresenius's perspective. The expanding distribution network happened over the second half of the year last year. We are now dealing with, we are now dealing through, a distribution network that covers 55% of the ConvaTec business, meaning that ConvaTec a revenue of NOK 200 million. Now we have distribution in the geographies that covers 55% of the NOK 200 million. The rights issue, yes, at the end of the year we did go through a process where we raised additional NOK 35.7 million, whereof NOK 21 million was cash. A little bit back to the commercial journey on the UnoMeter side. What you see here is that on the potential of the business is NOK 200 million. That is the revenue that ConvaTec had on the UnoMeter brand. As I mentioned before, we actually now have access, or we had access at the end of the year, of 55%. Since then, we have made additional agreements. Nordic, Germany, Switzerland, and Ireland are now also part of the distribution portfolio. So therefore, now we are actually at 75%, covering 75% of the of the geography that ConvaTec had. We did deliver the first major shipments of the UnoMeter in November and December, going to a number of countries. The first one was Poland, the second one Spain, Italy, and now we are actually in a situation where we have delivered all customers the first orders. So that was a major achievement for us. What we've also seen now is that, the focus now is twofold. First of all, we want to make sure that the distribution network we have set up are actually able to promote the product, our products successfully. So that's very much a part of our focus right now. But we do also focus on expanding the geography further. So on the map, so to speak, and on the priority list, there's France, Australia, New Zealand, Belgium, and Argentina are the ones we see within our short-term reach. At least that's our priorities. This is the pipeline we are looking at in the next two years. What we've seen on the left-hand side is the UnoMeter 500 and the Abdo-Pressure. Those products have been launched, and we are continuously growing our market share on those products. We do have, for this year, additional ambitions to launch the Safeti Plus project and also the combination, the pre-connected version of a Safeti Plus with the Abdo-Pressure. The Safeti Plus was, without comparison, the most interesting product that ConvaTec had. That was around 70%-75% of their total revenue coming from that product. So for us, UnoMeter 500 gave us access to the market. The UnoMeter Safeti Plus would give us the volume of the market. Abdo-Pressure is important, and the pre-connected one is important. It gives us access to many customers. It's a very unique product. So that's important. Not from a volume revenue perspective, but access. It is unique and therefore something that the distributors are looking for. Looking into next year, we have quite ambitious plans in terms of launching the UnoMeter Safeti Max. It's an improvement to the Safeti Plus, obviously, within the infection technology. Already now we have access to this technology. It's a patented technology that is developed in relation to Sippi. We want to exploit that into the, into the manual urometers. And what you could say is that 2024 ambitions will bring us back to where ConvaTec was once one and a half years ago. Next year, we will take the next steps in exceeding and going into products that are unique to the market, which is, of course, our ambitions, both with the Sippi and the UnoMeter Safeti Max. Maybe a few comments, Rune, on the, on the product development side, on that side. [Foreign language] Ja, takk skal du ha, Jørgen. Jeg går over på norsk her. Som Jørgen har snakket om her, så har vi fått et veldig godt porteføljefundament som vi kan ta i en rekkefølge ut i markedet. Og i parallell med distribusjonsnettverket som satt opp, så har vi også sikret at vi kan gjøre de rette tingene for å få dette satt i produksjon hos gode produsenter som kan produsere til rett pris, kan produsere til rett kvalitet, og kan levere det som markedet etterspør. Så slik som det ser ut nå, så det planen vår å gjøre det i den rekkefølgen som Jørgen har beskrevet. Og det handler også om å gjøre ting riktig i forhold til det distributørene ønsker å ha. Safety Plus har vi store forventninger til, har hatt historisk salg før ConvaTec. Og så det veldig spennende å rette blikket mot 2025 og se på effekten av Sippi når vi kan legge den på toppen av den porteføljen som vi nå etablerer, og gir tilgang til de kundene som har både ønsket og har etterspurt det produktet. Så uten å gå inn på for mange tekniske detaljer, så overlater jeg ordet til Jørgen og Johan videre i presentasjonen. Takk. Thanks, Rune. Rune. Regarding Biim, this is a project that has been going on for some time, you will know that, most of you. The focus has been, and continues to be, to develop a partnership with Fresenius. Fresenius is, without comparison, the biggest player within the dialysis field. We've some time ago concluded that the most obvious opportunity for Biim, based on its functionality, is the dialysis segment. Dialysis segment is a huge opportunity for us. Just that one on a global basis is a huge opportunity. When you zoom in to Fresenius, you would see that even Fresenius on its own has a huge opportunity, or is a huge opportunity. The challenge will always be with a company that has 130,000 employees, is that it's a bigger super tanker to get them on board. They did buy back in 2023/22 285 probes. For them and for us, it has been kind of a pilot project. They wanted to take it in, make sure that this product actually offered both the sort of clinical outcome that they were looking for, but also giving them a business case that meant that if they invested, they would also get more effective dialysis treatments. What Fresenius is doing in the U.S. is running almost 3,000 clinics. Therefore, they are treating new patients every second almost, meaning that just an improvement of the effectiveness of the treatment would mean a lot to them. What has been seen very recently is that Fresenius has been working on a journey that would prove that there is a business case behind investing in Biim. And actually, just very recently, they came out with the first results, and they did show that a number of clinical processes, if you like, would be more effective working with the Biim product. And this is the first time they have come to that conclusion. That would be fundamental for their decision on how to move forward with Biim. So a major step, as we see it. We also have now formed an internal project group to explore some parallel tracks, whether we can actually explore some alternative strategies for Biim. As I mentioned, the downside of running with a huge company is the speed. We are going to explore other opportunities that will give us, hopefully, a faster track to a market entry and a commercial exploitation of the Biim product. That was it from the commercial side. Johan, please. [Foreign language] Takk skal du ha, Jørgen. Yes, jeg har fått glede av å presentere tall for andre halvår og fullår 2023. Så jeg tenker vi kan bare starte rett på. Vi endte på en revenue på NOK 27.9 million for året. Det en vekst på 43% fra året før. Som vi også ser, så størstedelen av den veksten kommet i andre halvår 2023. Det jo da drevet av, som Jørgen sa, leveranse av UnoMeter i Q4. Ser vi på gross profit, så endte den på NOK 9.3 million for året og NOK 5 million i andre halvår. Det gir en margin på 33% og 31% for andre halvår. Det en stor økning fra samme tid på året før. Men hvis vi isolerer da en varelager-nedskriving vi hadde i Q4 2022, så vi marginmessig på nivå med året før. Ser vi på kostnadene, så jeg kommer litt tilbake til det etterpå, men i andre halvår så vi NOK 7.7 millioner lavere enn samme tid i året før. Totalt sett for året, så sammenligner vi med 2022, så kan vi huske det at vi har bare 10 måneder med Biim integrert i det konsernregnskapet. Så det vi har ikke hele fullårseffekten. Vi har fått fullårseffekten av Biim inn i 2023. EBITDA før non-recurring endte vi på -NOK 34.3 millioner, og -NOK 14.9 millioner i andre halvår. Non-recurring i denne sammenheng, det da investeringer vi har gjort som ikke ble videreført. Og det da relatert til ConvaTec-porteføljen og det oppkjøpet som var planlagt av Ferrari L.-fabrikken i Italia. Hvis vi går videre, da så har vi negativ nettofinans. Vi har en liten økning i avskrivninger som skyldes fullårseffekten av Biim primært. Noe som gjør at vi lander på et resultat for året på NOK -60.3 millioner, og NOK -25.1 millioner for andre halvår. Når det gjelder driftskostnader, så har vi hatt en reduksjon på det. Og det er et resultat av aktive grep som er gjort for å ta ned cashburn og risiko. I andre halvår så har det vært gjort utstrakt permitteringer og nedbemanning. Vi har tatt ned bruk av konsulenter. Vi har redusert kontorleie og antall firmabiler. Og vi forventer jo da å se fullårseffekten av dette også nå i 2024. Så i tillegg jobber vi jo da med kontinuerlige... Ser Ser på muligheter da for å optimalisere driften ytterligere. Når det sagt, så har vi jo en ambisiøs vekst neste år og 2025. Så vi er nødt til å styrke organisasjonen med riktig kompetanse fremover også, for å sikre de vekstmålene vi har satt. Ser vi på eiendelsiden, så det er vel én vesentlig endring her, og det at vi har tatt inn kjøpet av UnoMeter fra ConvaTec. Goodwill-endringen er små. Det skyldes da valutasvingninger kun. En total assets på NOK 252 million. Cashen kommer jeg tilbake til etterpå. Vi har en total egenkapital på NOK 116.3 million. Det er en egenkapitalandel på 46%. Vi har fått inn en non-current liabilities på NOK 25 million. Det er da det langsiktige avdraget på betalingen til ConvaTec for UnoMeter på $2.4 million. Forfall er der september 2025. Vi har en økning i leverandørgjeld. Det er primært et resultat av at vi aktivt i andre halvår har jobbet med betalingsavtaler med våre leverandører. Størstedelen av dem har gått med på en tolvmåneders betalingsplan, eller en utsettelse av betalingen i tolv måneder, mot en 10% årlig rente. Så har vi den kortsiktige delen av UnoMeter, som ligger nede på other current liabilities, på $1.5 million som har forfall ved utgangen av 2024. Netto rentebærende gjeld på NOK 43.2 million. Det er en nedgang i andre halvår, og det skyldes jo da cash-settlementen og konverteringen av gjeld i rights issue, som var i desember. Ser vi kort på cashflowen, så er jo da cashflow brukt i operasjonell aktivitet et resultat av resultatet, justert for elementer uten cash-effekt og endring i working capital. Av investeringer så har vi brukt NOK 7.6 million, $300,000 i cash-vederlag upfront til ConvaTec. Resterende brukt i prosjekt for å sette opp produksjon og få klargjort UnoMeter til markedet. Så har vi jo da finansielle aktiviteter. Det er jo net proceeds fra rights issue, og et lån på NOK 5 million fra Navamedic. Det gir oss en cashbeholdning ved utgangen av året på NOK 13.7 million. Med det gir jeg ordet til Jørgen igjen. 2024 deliverables, what are the main deliverables we're looking for? Many of them have already been mentioned. The first chop of priorities will be the launch of the products UnoMeter Safeti Plus and the Abdo-Pressure pre-connected version. They are the products that will bring us into a position where we will take major market share, because that is the major product, the foundation that ConvaTec also had. So that will be the product that will lead us to the next step commercially. We also, as I mentioned, have now more than 25 countries selling our products. And we need to make sure that now they have most of them gotten their first delivery. We need to make sure that they are able to win the tenders, win the business that would pave the way to launch the Safeti Plus. So that's a big focus right now. We need to basically support them in terms of logistical performance, but also a number of other marketing-related issues. We need to continue to deliver the distribution network. This is crucial, you could say, is what we have not enough. It's not, because the ambition is quite a lot higher than what we can cover with the current 55%, as we saw in the beginning. So this is definitely a priority for us to continue the geographical expansion on the distribution side. And as I mentioned in the beginning, we also have the opportunities to explore, or let's say utilize our distribution network for other companies' products. That's also one of the projects that Rune will be working with. How can we find and attract those products where companies will have products, but not a sales distribution network? Behind all this, there are some fundamental challenges that we need to deal with. On the financial side, we want to move this very speedily. And of course, that would challenge us on our capital situation. The liquidity is under some pressure in terms of how fast we can implement these projects. This is something we're obviously working on. At the same time, we're working on, let's say, dismantling some of the complexity that we have in the company. You saw some of the effects of how we manage cost, and we want to continue that journey of dismantling that complexity. So that's, from a sort of a background perspective, some of the priorities that we are looking at right now and making sure we can make sure we can execute on the ambitions we have. All right, I think that was the presentation. Thank you for listening. We move into the Q&A session. Jeg vil se om det er noen spørsmål fra salen før vi går over på web. [Foreign language] Hei, Andreas Vangstad. Kan dere si noe om marginbildet etter dere tok over UnoMeter-porteføljen fra ConvaTec? Den i bedring i forhold til hva de fikk? Jeg så at de hadde vel rundt 30% i snitt. Yeah, I can put some words to that. We are right now selling the UnoMeter 500 with a margin in the early 30s, so a little bit better than what ConvaTec did. We have a little bit more effective platform, and the market has also, due to the fact that ConvaTec retracted, the market price has increased. So that has helped us. The major opportunity we see will be the Safeti Plus. That offers some differentiating elements that would strengthen our position in the different markets that would drive an increased margin. Over time, the margin on UnoMeter 500 will be challenged. We already have defined a small project that would, let's say, improve the cost picture of the UnoMeter 500, because UnoMeter 500 will come under pressure as the market becomes more normal, so we have to become more effective there. That was a long answer. Did I capture that? Yeah. Thanks. [Foreign language] Kan du også si noe om når dere forventer at Safeti Plus vil komme til markedet? Well, there is a, let's say there are two parts of the development project. That is the regulatory part, getting the CE mark under that product as well, under our own umbrella, and also getting the product, let's say the manufacturing equipment established. Right now, we're looking at end of Q3 or Q4. [Foreign language] Da har vi kun ett spørsmål fra web. Kan dere utdype utover hva som står i rapporten, hva status på Biim, herunder salg av flere enheter til Fresenius? Yes. I think I did mention that one fundamental conclusion that Fresenius has been waiting for is the one I was referring to before, the fact that Biim will actually not only improve the quality of the treatments, but also improve the financials of the clinics that Fresenius is running. We are now closer to the conclusion that it actually does improve the profitability. It's a positive business case to invest in Biim. This is going to be escalated into a higher level into Fresenius. Exactly when they will make that decision is a little bit out of our hands. So it's going to be very difficult to predict that. So it's just too unsecure to make a specific judgment on the timing of this right now. Takk. All right. That's the end of us.